Synovitis in osteoarthritis: the current state of the problem

Дыдыкина, И. С.; Арутюнова, Е. В.; Коваленко, П. С.; Николаева, Е. В.; Наумов, А. В.

doi:10.14412/1996-7012-2021-2-120-125

Cited by 1 publication

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ХС -один из наиболее изученных препаратов для терапии ОА, который обладает симптом-и структурно-модифицирующими свойствами, способствует активации синтеза протеогликанов, уменьшению выраженности воспаления в синовиальной оболочке (СО) за счет снижения активности простагландинов и ферментов, уменьшает боль [5]. Воспаление СО является частым, а в некоторых случаях -единственным клиническим проявлением ОА, а его выраженность коррелирует с тяжестью симптомов ОА [6].…”

unclassified

See 1 more Smart Citation

Evaluation of the impact of a course of therapy with an injectable form of chondroitin sulfate on the duration of remission and quality of life in patients with osteoarthritis

Kovalenko,

Dydykina,

Alekseeva

et al. 2023

Sovremennaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Ensuring a long-lasting effect of the therapy and its safety are important tasks in the treatment of patients with osteoarthritis (OA). Parenteral forms of chondroitin sulfate (CS) used for the background therapy of OA are characterized by proven efficacy and safety and, compared to oral forms, have greater bioavailability, faster onset of symptom-modifying effect and maintenance of more stable remission, which can significantly improve patients' quality of life.Objective: to evaluate the clinical efficacy and safety of two-month therapy with injectable CS and the duration of positive dynamics after the end of treatment in patients with knee OA (KOA).Material and methods. The open prospective observational study involved 35 patients (mainly women) aged 50–75 years with stage II–III KOA. All patients were prescribed intramuscular therapy with a CS solution (Mucosat® solution), with the first three injections of 1 ml, followed by 2 ml every second day (25 injections in total). Standard indices and questionnaires were used to assess the main clinical indicators at baseline and over time (14, 30, 60 days, 5 and 8 months after the start of treatment), as well as the results of ultrasound examination of the knee at baseline and at the end of treatment.Results and discussion. 14 days after the start of therapy, a statistically significant decrease in pain was observed applying the visual analogue scale (VAS), and after 2 months, 94% of patients had a significant decrease in knee pain according to VAS, Lequesne index and WOMAC index (total score and components). The KOOS parameters and quality of life according to EQ-5D-3L improved significantly. There was no pain or only minor pain (VAS ≤40 mm) in 54% of patients. The number of patients who had to take nonsteroidal anti-inflammatory drugs (NSAIDs) constantly fell threefold, while occasional use fell fivefold. The thickness of the synovial membrane of the knee joint and the number of patients with signs of synovitis decreased significantly. At 3 and 6 months after the end of therapy, most patients (60%) still had minor pain (≤40 mm according to VAS) and a significantly lower need for NSAIDs compared to baseline. The injectable CS was well tolerated and no adverse drug events were noted.Conclusion. We demonstrated both safety and efficacy and long-term maintenance of the clinical effect (6 months after the end of therapy) of injectable CS in the majority of OA patients, against the background of a low need for NSAIDs.

show abstract

unclassified

“…Дыдыкиной и соавт. [6]. Отличительной особенностью настоящего исследования является изучение длительности и выраженности клинического эффекта, который сохранялся после завершения курса терапии ХС.…”

unclassified